Contract-Resource-Outsourcing-IndustryNews

61. Hovione's TwinCaps Inhaler In Phase III Clinical Trials For Influenza 4/16/2009
    Hovione is pleased to announce that its licensee Daiichi Sankyo (Tokyo, Japan) has informed that it intends to use Hovione’s TwinCaps dry powder inhaler device in the launch of the compound CS-8958, an inhaled long-acting neuraminidase inhibitor active against the influenza virus.
62. Merck & Co., Inc. And Cardiome Sign License Agreement For Vernakalant, An Investigational Drug For Treatment Of Atrial Fibrillation 4/12/2009
    Merck & Co., Inc. and Cardiome Pharma Corp. recently announced a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation.
63. Clinsys Partners With N.C. State University For Six Sigma Green Belt Training 4/7/2009
    Clinsys Clinical Research, Inc., a therapeutically focused global contract research organization, announced its partnership with North Carolina State University (NCSU) to provide 20 Clinsys employees with Six Sigma Green Belt training.
64. Ixiaro® Vaccine Receives Marketing Authorization In Europe To Prevent Japanese Encephalitis 4/6/2009
    The European Commission has granted Marketing Authorization to Ixiaro® vaccine for the prevention of Japanese Encephalitis (JE).
65. Afinitor® Approved In US As First Treatment For Patients With Advanced Kidney Cancer 3/31/2009
    Novartis announced today that Afinitor® (everolimus) tablets has been approved by the US Food and Drug Administration (FDA) for patients with advanced renal cell carcinoma (RCC) after failure of treatment with Sutent® (sunitinib) or Nexavar® (sorafenib).
66. Zydus Cadila Announces Research Collaboration To Discover And Develop New Cardiovascular Medicines 3/31/2009
    Zydus Cadila, a global healthcare group headquartered in India has signed a new drug discovery and development agreement with Eli Lilly and Company focused in the area of cardiovascular research.
67. FluGen Secures Exclusive Rights To Novel Vaccine-Delivery Technology 3/31/2009
    FluGen Inc., an emerging leader in the development, production and delivery of influenza vaccines and related products, today announced it has secured exclusive rights to a novel, patent-protected vaccine-delivery technology being commercialized by Madison, Wis.-based Ratio Inc. Terms of the license agreement were not disclosed.
68. Cervarix U.S. Regulatory Update 3/31/2009
    GlaxoSmithKline recently provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX, its vaccine to prevent cervical cancer and cervical pre-cancer related to human papillomavirus types 16 and 18.
69. Evotec Restructures And Implements 'Evotec 2012 - Action Plan To Focus And Grow' 3/31/2009
    Evotec AG recently announced that it will restructure to focus on core value programs and significantly reduce its operating costs.
70. OSI Pharmaceuticals Submits Supplemental New Drug Application To The FDA For Tarceva As A First-Line Maintenance Therapy In Advanced Non-Small Cell Lung Cancer 3/24/2009
    OSI Pharmaceuticals, Inc. and Genentech, Inc., recently announced that OSI submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the use of Tarceva (erlotinib) as a first-line maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) who have not progressed following first-line treatment with platinum-based chemotherapy.